Drugs / SAB-142
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07187531 | Nov 2025 → Nov 2027 expected | type 1 diabetes mellitus | SAb Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07670650 | Sep 2026 → Mar 2029 expected | type 1 diabetes mellitus | University of Florida | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-29 | Emergent BioSolutions | Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 emergentbiosolutions.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAB 142 | “This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with...” NCT07187531 ↗ |
| Modality | Protein / enzyme biologic | “Human Anti-thymocyte ImmunoGlobUlin SAB-142” NCT07187531 ↗ |
| Route | Intravenous | “SAB-142 0.5 mg/kg IV” NCT07670650 ↗ |